SARS-CoV-2 triggers complement activation through interactions with heparan sulfate.

Martin W LoAlberto A AmarillaJohn D LeeEduardo A AlbornozNaphak ModhiranRichard J ClarkVito FerroMohit ChhabraAlexander A KhromykhDaniel WattersonTrent M Woodruff

Published in: Clinical & translational immunology (2022)

SARS-CoV-2 is a noncanonical alternative pathway activator that progressively triggers complement activation through interactions with heparan sulfate.

Keyphrases

sars cov
respiratory syndrome coronavirus